Loading...
•
Mar 31, 2024
Dyne Therapeutics Q1 2024 Earnings Report
Dyne Therapeutics reported financial results for Q1 2024 and recent business highlights.
Key Takeaways
Dyne Therapeutics reported a net loss of $65.6 million for the first quarter of 2024. The company's cash, cash equivalents, and marketable securities totaled $453.5 million as of March 31, 2024, which are anticipated to fund operations through 2025.
John Cox was appointed president, CEO, and a member of the Board of Directors in March 2024.
The ACHIEVE trial of DYNE-101 and the DELIVER trial of DYNE-251 are ongoing and recently completed enrollment in the 6.8 mg/kg Q8W cohort and the 40 mg/kg Q8W cohort, respectively.
Positive initial clinical data from ACHIEVE and DELIVER reported in January 2024 were featured in oral presentations at scientific conferences in March and April 2024.
Dyne anticipates reporting data from multiple, higher dose cohorts from both the ACHIEVE and DELIVER trials in the second half of 2024 with the goal of initiating registrational cohorts by the end of 2024.
Dyne Therapeutics
Dyne Therapeutics
Forward Guidance
Dyne anticipates reporting data from multiple, higher dose cohorts from both the ACHIEVE and DELIVER trials in the second half of 2024 with the goal of initiating registrational cohorts by the end of 2024.